NAL Pharmaceuticals Ltd. - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'NAL Pharmaceuticals Ltd. - Product Pipeline Review - 2016', provides an overview of the NAL Pharmaceuticals Ltd.'s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by NAL Pharmaceuticals Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of NAL Pharmaceuticals Ltd. - The report provides overview of NAL Pharmaceuticals Ltd. including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses NAL Pharmaceuticals Ltd.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features NAL Pharmaceuticals Ltd.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate NAL Pharmaceuticals Ltd.'s strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for NAL Pharmaceuticals Ltd. - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding NAL Pharmaceuticals Ltd.'s pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 NAL Pharmaceuticals Ltd. Snapshot 6 NAL Pharmaceuticals Ltd. Overview 6 Key Information 6 Key Facts 6 NAL Pharmaceuticals Ltd. - Research and Development Overview 7 Key Therapeutic Areas 7 NAL Pharmaceuticals Ltd. - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 NAL Pharmaceuticals Ltd. - Pipeline Products Glance 12 NAL Pharmaceuticals Ltd. - Early Stage Pipeline Products 12 Preclinical Products/Combination Treatment Modalities 12 Discovery Products/Combination Treatment Modalities 13 NAL Pharmaceuticals Ltd. - Unknown Stage Pipeline Products 14 Unknown Products/Combination Treatment Modalities 14 NAL Pharmaceuticals Ltd. - Drug Profiles 15 pegfilgrastim 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 montelukast sodium 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 diclofenac sodium 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 donepezil hydrochloride 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 donepezil hydrochloride Patch 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 formoterol fumarate 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 galantamine hydrobromide 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 indomethacin 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 ketoprofen 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 levocetirizine dihydrochloride 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 NAL-3216 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 NAL-3221 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 NAL-3223 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 nicotine bitartrate 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 rizatriptan benzoate 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 sildenafil citrate 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 sufentanil citrate 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 tadalafil 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 tulobuterol 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 NAL Pharmaceuticals Ltd. - Pipeline Analysis 34 NAL Pharmaceuticals Ltd. - Pipeline Products by Target 34 NAL Pharmaceuticals Ltd. - Pipeline Products by Route of Administration 36 NAL Pharmaceuticals Ltd. - Pipeline Products by Molecule Type 37 NAL Pharmaceuticals Ltd. - Pipeline Products by Mechanism of Action 38 NAL Pharmaceuticals Ltd. - Dormant Projects 39 NAL Pharmaceuticals Ltd. - Locations And Subsidiaries 40 Head Office 40 Appendix 41 Methodology 41 Coverage 41 Secondary Research 41 Primary Research 41 Expert Panel Validation 41 Contact Us 41 Disclaimer 42
List of Tables
NAL Pharmaceuticals Ltd., Key Information 6 NAL Pharmaceuticals Ltd., Key Facts 6 NAL Pharmaceuticals Ltd. - Pipeline by Indication, 2016 8 NAL Pharmaceuticals Ltd. - Pipeline by Stage of Development, 2016 10 NAL Pharmaceuticals Ltd. - Monotherapy Products in Pipeline, 2016 11 NAL Pharmaceuticals Ltd. - Preclinical, 2016 12 NAL Pharmaceuticals Ltd. - Discovery, 2016 13 NAL Pharmaceuticals Ltd. - Unknown, 2016 14 NAL Pharmaceuticals Ltd. - Pipeline by Target, 2016 35 NAL Pharmaceuticals Ltd. - Pipeline by Route of Administration, 2016 36 NAL Pharmaceuticals Ltd. - Pipeline by Molecule Type, 2016 37 NAL Pharmaceuticals Ltd. - Pipeline Products by Mechanism of Action, 2016 38 NAL Pharmaceuticals Ltd. - Dormant Developmental Projects,2016 39
List of Figures
NAL Pharmaceuticals Ltd. - Pipeline by Top 10 Indication, 2016 8 NAL Pharmaceuticals Ltd. - Pipeline by Stage of Development, 2016 10 NAL Pharmaceuticals Ltd. - Monotherapy Products in Pipeline, 2016 11 NAL Pharmaceuticals Ltd. - Pipeline by Top 10 Target, 2016 34 NAL Pharmaceuticals Ltd. - Pipeline by Top 10 Route of Administration, 2016 36 NAL Pharmaceuticals Ltd. - Pipeline by Molecule Type, 2016 37 NAL Pharmaceuticals Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2016 38
Global engineering service outsourcing market size is likely to be valued at USD 415.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Rapid alignment of OEMs accompanied by increasing focus on efficient performance and reliabRead More...
Global embedded system market is projected to be valued at USD 214.39 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising demand from end-use industries such as automotive and healthcare coupled with emergence of Internet oRead More...
Global 3D scanning market is expected to be valued at USD 4,900.7 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing need for speedy and precise results with high efficiency is anticipated to drive the industry. 3DRead More...
Global Automated Test Equipment (ATE) market is expected to be valued at USD 4.48 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing design complexity coupled with need for effective testing is expected to drive the glRead More...
Global lignin market size is expected to exceed USD 6 billion by 2022, growing at 4.9% from 2015 to 2022. Rising demand for animal feed and potential as a feedstock substitute to crude oil are expected to drive lignin market demand over the forecastRead More...
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.